Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Asset Writedowns and Impairment (2017 - 2022)

Historic Asset Writedowns and Impairment for Silo Pharma (SILO) over the last 6 years, with Q1 2022 value amounting to -$20000.0.

  • Silo Pharma's Asset Writedowns and Impairment fell 16666.67% to -$20000.0 in Q1 2022 from the same period last year, while for Dec 2022 it was -$20000.0, marking a year-over-year increase of 8653.2%. This contributed to the annual value of -$20000.0 for FY2022, which is 8653.2% up from last year.
  • Latest data reveals that Silo Pharma reported Asset Writedowns and Impairment of -$20000.0 as of Q1 2022, which was down 16666.67% from -$65000.0 recorded in Q4 2021.
  • In the past 5 years, Silo Pharma's Asset Writedowns and Impairment ranged from a high of $75376.0 in Q4 2020 and a low of -$65000.0 during Q4 2021
  • For the 5-year period, Silo Pharma's Asset Writedowns and Impairment averaged around -$7960.5, with its median value being -$13750.0 (2021).
  • Per our database at Business Quant, Silo Pharma's Asset Writedowns and Impairment surged by 11886.18% in 2020 and then tumbled by 18623.43% in 2021.
  • Silo Pharma's Asset Writedowns and Impairment (Quarter) stood at -$5000.0 in 2018, then surged by 788.8% to $34440.0 in 2019, then surged by 118.86% to $75376.0 in 2020, then crashed by 186.23% to -$65000.0 in 2021, then surged by 69.23% to -$20000.0 in 2022.
  • Its Asset Writedowns and Impairment stands at -$20000.0 for Q1 2022, versus -$65000.0 for Q4 2021 and -$37500.0 for Q3 2021.